Details of the Drug Combination

General Information of Drug Combination (ID: DCYGOD5)

Drug Combination Name
Itopride Norfloxacin
Indication
Disease Entry Status REF
Spontaneous Bacterial Peritonitis Phase 3 [1]
Component Drugs Itopride   DM7MLTR Norfloxacin   DMIZ6W2
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Itopride Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Dimethylaniline oxidase 3 (FMO3) DEP76YL FMO3_HUMAN Metabolism [4]
------------------------------------------------------------------------------------
Itopride Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Decreases Activity [5]
------------------------------------------------------------------------------------
Indication(s) of Norfloxacin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [2]
Acute maxillary sinusitis N.A. Approved [2]
Anthrax 1B97 Approved [2]
Bacillary dysentery 1A02 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Bronchitis CA20 Approved [2]
Chancroid N.A. Approved [2]
Chronic tubotympanic suppurative otitis media N.A. Approved [2]
Cystitis GC00 Approved [2]
Endomyometritis N.A. Approved [2]
Malignant otitis externa caused by Pseudomonas aeruginosa N.A. Approved [2]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Peritonitis N.A. Approved [2]
Pneumonia CA40 Approved [2]
Prostatitis N.A. Approved [2]
Pyelonephritis N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Streptococcal pneumonia N.A. Approved [2]
Traveler's diarrhea ME05.1 Approved [2]
Urinary tract infection GC08 Approved [2]
Pneumonia caused by chlamydia N.A. Investigative [2]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [2]
Norfloxacin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [6]
------------------------------------------------------------------------------------
Norfloxacin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Norfloxacin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Norfloxacin Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Increases Expression [11]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [11]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Affects Activity [11]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Decreases Expression [12]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [11]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Affects Binding [13]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Affects Activity [11]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [11]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 ClinicalTrials.gov (NCT04161768) Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
2 Norfloxacin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074690.
4 Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
5 Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. Toxicol Lett. 2015 Feb 3;232(3):557-65.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8 Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
9 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
10 Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
11 Norfloxacin induces apoptosis and necroptosis in human corneal epithelial cells. Toxicol In Vitro. 2020 Aug;66:104868. doi: 10.1016/j.tiv.2020.104868. Epub 2020 Apr 19.
12 Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology (Oxford). 2005 Dec;44(12):1514-7. doi: 10.1093/rheumatology/kei087. Epub 2005 Sep 7.
13 Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021 Jun 30;458:152822. doi: 10.1016/j.tox.2021.152822. Epub 2021 May 28.
14 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.